Sanofi (EPA:SAN)
France · Delayed Price · Currency is EUR 75.29
-1.07 (-1.40%)
May 29, 2026, 5:39 PM CET
Sanofi Employees
Sanofi had 74,846 employees as of December 31, 2025. The number of employees decreased by 8,032 or -9.69% compared to the previous year.
Employees
74,846
Change (1Y)
-8,032
Growth (1Y)
-9.69%
Revenue / Employee
€632,686
Profits / Employee
€100,941
Market Cap
90.36B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 74,846 | -8,032 | -9.69% |
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 155,975 |
| emeis Société anonyme | 84,586 |
| Clariane SE | 70,685 |
| Eurofins Scientific SE | 65,694 |
| Ramsay Générale de Santé | 40,000 |
| bioMérieux | 15,226 |
| Sartorius Stedim Biotech | 10,456 |
| Virbac | 6,442 |
Sanofi News
- 3 days ago - Sanofi (SNY) Receives FDA Priority Review for Venglustat Application - GuruFocus
- 3 days ago - Sanofi announces FDA grants priority review to venglustat new drug application - TheFly
- 3 days ago - Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease - GlobeNewsWire
- 4 days ago - Sanofi is building its own AI ecosystem to give the French pharma giant an edge - Fortune
- 12 days ago - Sanofi: Information concerning the total number of voting rights and shares - April 2026 - GlobeNewsWire
- 12 days ago - Sanofi Reports Positive Phase 2 Data For Efdoralprin Alfa In AATD-Related Emphysema - Finanz Nachrichten
- 13 days ago - Sanofi (SNY) Presents Promising Phase 2 Study Results for Efdoralprin Alfa - GuruFocus
- 13 days ago - 1 Dirt Cheap Growth Stock to Buy Right Now - The Motley Fool